Jubilant DraxImage Appoints New Member of its Executive team

Addition of Mr. Kevin Brooks strengthen further Jubilant DraxImage expertise

MONTREAL, April 2, 2013 /PRNewswire/ - Jubilant DraxImage Inc. (hereinafter "JDI"), a Jubilant Life Sciences Company, is pleased to announce the appointment of Mr. Kevin Brooks in the role of Vice President Sales, Marketing and Business Development with effect from today.

With more than twenty years of progressive commercial experience in the specialty pharmaceuticals and targeted medical device markets, Kevin Brooks is a seasoned leader with a strong understanding of business and global radiopharmaceutical market dynamics.  Martyn Coombs, President of Jubilant DraxImage stated; "Kevin's expertise in conceptualizing and launching new products as well as rejuvenating mature product lines will be a significant asset to Jubilant Draximage."

Kevin joins Jubilant DraxImage from Nordion Inc., where he recently served as Senior Vice President of Sales and Marketing and a member of the Executive Management Team, responsible for the company's Global Sales, Marketing, Customer Service and Business Development functions.  Prior to joining Nordion in July 2006, Kevin served as Global Marketing Director Nuclear Cardiology at GE Healthcare, where he led marketing and cross-functional brand team initiatives for Myoview, a SPECT myocardial perfusion agent.  Earlier, he worked with Bracco Diagnostics Inc., as Marketing Director Nuclear Medicine, responsible for the company's generic and branded radiopharmaceutical products, which included Rb-82 generators, 99mTc-cold kits and I-131 radioiodine therapy products.

He holds a Bachelor of Health Science from Gwynedd Mercy College (Pennsylvania) and a Master of Business Administration from Temple University (Philadelphia, PA) as well as being a former Nuclear Medicine Technologist and Medical Sonographer.

About Jubilant DraxImage Inc.
Jubilant DraxImage Inc., a subsidiary of Jubilant Life Sciences, develops, manufactures and markets diagnostic and therapeutic radiopharmaceuticals for the global nuclear medicine marketplace. Jubilant DraxImage Inc.'s mission is to be a leading global provider of radiopharmaceuticals and value-added enabling technologies. Products include a proprietary line of lyophilized Technetium-99m kits (MAA, MDP, DTPA and Sestamibi). Jubilant DraxImage Inc. is also a leading supplier of I-131 radiopharmaceuticals in North America, used for the diagnosis and treatment of thyroid disorder and cancer. Jubilant DraxImage Inc. products are exported worldwide, with regulatory approvals in USA, South America, parts of Europe and South Asia. More information about Jubilant DraxImage is available at www.draximage.com.

SOURCE Jubilant DraxImage Inc.